<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714740</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1522</org_study_id>
    <nct_id>NCT00714740</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude</brief_title>
  <official_title>Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effect of acetazolamide as a treatment for
      sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome
      living at low altitude during a sojourn at moderate altitude
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep disordered breathing, sleep structure, vigilance, subjective sleep quality acute mountain sickness</measure>
    <time_frame>during treatment while at altitude</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure endothelial function</measure>
    <time_frame>during treatment while at altitude</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">49</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetazolamide</intervention_name>
    <description>acetazolamide 2 times 250mg per day</description>
    <other_name>Diamox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obstructive sleep apnea syndrome, successfully on CPAP therapy

          -  Residence at low altitude (&lt;800m)

          -  Obstructive apnea/hypopnea index &gt;20/h and a complaint of excessive daytime sleepiness
             before introduction of CPAP therapy.

          -  &gt;15 oxygen desaturations/h (&gt;3% dips) during an ambulatory nocturnal pulse oximetry
             performed at the end of a 4-night period without CPAP

        Exclusion Criteria:

          -  Sleep disorders other than OSA.

          -  More than mild cardiovascular disease, unstable or recently diagnosed (within the last
             6 months) cardiovascular disease such as arterial hypertension, coronary artery or
             cerebrovascular disease.

          -  Any lung disease, pulmonary hypertension.

          -  Chronic rhinitis.

          -  Treatment with drugs that affect respiratory center drive (benzodiazepines or other
             sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants
             (modafinil, methylphenidate, theophylline)

          -  Internal, neurologic or psychiatric disease that interfere with sleep quality.

          -  Previous intolerance to moderate or low altitude (&lt;2600m).

          -  Exposure to altitudes &gt;1500m for &gt;1 day within the last 4 weeks before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pulmonary Division, University Hospital Zurich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Division, University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Nussbaumer-Ochsner Y, Latshang TD, Ulrich S, Kohler M, Thurnheer R, Bloch KE. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest. 2012 Jan;141(1):131-138. doi: 10.1378/chest.11-0375. Epub 2011 Jun 9.</citation>
    <PMID>21659435</PMID>
  </reference>
  <reference>
    <citation>Ulrich S, Nussbaumer-Ochsner Y, Vasic I, Hasler E, Latshang TD, Kohler M, Muehlemann T, Wolf M, Bloch KE. Cerebral oxygenation in patients with OSA: effects of hypoxia at altitude and impact of acetazolamide. Chest. 2014 Aug;146(2):299-308. doi: 10.1378/chest.13-2967.</citation>
    <PMID>24811331</PMID>
  </reference>
  <reference>
    <citation>Stadelmann K, Latshang TD, Nussbaumer-Ochsner Y, Tarokh L, Ulrich S, Kohler M, Bloch KE, Achermann P. Impact of acetazolamide and CPAP on cortical activity in obstructive sleep apnea patients. PLoS One. 2014 Apr 7;9(4):e93931. doi: 10.1371/journal.pone.0093931. eCollection 2014.</citation>
    <PMID>24710341</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <last_update_submitted>May 18, 2014</last_update_submitted>
  <last_update_submitted_qc>May 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apnea, sleep, altitude, hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

